生存素调素(survodutide)——一种胰高血糖素/胰高血糖素样肽-1受体双重激动剂——在肝硬化中的疗效、耐受性和药代动力学
这项跨国、非随机、开放标签的I期临床试验评估了survodutide在肝硬化患者中的药代动力学和安全性:单次给药(0.3 mg)队列(n=41)中,肝硬化与健康个体的AUC0-∞和Cmax相似(校正几何均值比的90%CI跨越1);多次给药递增至6.0 mg、持续28周的队列(n=41)中,药物相关不良事件发生率分别为健康个体82.4%和肝硬化患者87.5%;28周后肝脏脂肪含量、肝硬度、肝脏体积、体重等指标总体下降。结论认为survodutide在代偿性或失代偿性肝硬化患者中总体可耐受,无需根据药代动力学调整剂量,可能改善肝脏相关无创检测指标,支持其用于MASH相关肝硬化的进一步研究。
要点
- 单次0.3 mg皮下给药后,肝硬化患者与健康个体的AUC0-∞和Cmax相似(校正几何均值比90%CI跨越1)。
- 多次给药递增至6.0 mg、持续28周,药物相关不良事件发生率健康个体82.4%、肝硬化患者87.5%。
- 28周治疗后肝脏脂肪含量、肝硬度、肝脏体积、体重等指标总体下降。
核心结论
- Survodutide在代偿性或失代偿性肝硬化患者中总体可耐受,无需根据药代动力学调整剂量,可能改善肝脏相关无创检测指标,支持其用于MASH相关肝硬化的进一步研究。
研究设计与样本
- 跨国、非随机、开放标签的I期临床试验(GOV IDENTIFIER: NCT05296733)。
- 单次给药队列(n=41):比较Child-Pugh A、B或C级肝硬化患者与年龄、性别、体重匹配的健康个体(伴或不伴超重/肥胖)单次皮下注射survodutide 0.3 mg的药代动力学。
- 多次给药队列(n=41):伴或不伴肝硬化(Child-Pugh A或B级)的超重/肥胖个体接受每周一次皮下给药,24周内从0.3 mg递增至6.0 mg,随后维持4周(共28周)。
主要发现
- 单次给药队列(n=41)中,肝硬化患者与健康个体的平均AUC0-∞和Cmax相似(校正几何均值比的90%CI跨越1)。
- 单次给药后药物相关不良事件发生率:健康个体25.0%,肝硬化患者≤25.0%。
- 多次给药队列(n=41)28周内药物相关不良事件发生率:健康个体82.4%,肝硬化患者87.5%。
- 28周survodutide治疗后,肝脏脂肪含量、肝硬度、肝脏体积、体重及其他肝脏和代谢疾病标志物总体下降。
关键数值与推荐
- 单次给药队列主要终点为AUC0-∞和Cmax;多次给药队列主要终点为药物相关治疗中出现的不良事件。
- 单次给药剂量为0.3 mg皮下注射;多次给药为每周一次皮下注射,24周内从0.3 mg递增至6.0 mg,随后维持4周。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Survodutide is a glucagon/glucagon-like peptide-1 receptor dual agonist in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). We investigated the pharmacokinetic and safety profile of survodutide in people with cirrhosis. METHODS: This multinational, non-randomized, open-label, phase I clinical trial initially evaluated a single subcutaneous dose of survodutide 0.3 mg in people with Child-Pugh class A, B or C cirrhosis and healthy individuals with or without overweight/obesity matched for age, sex, and weight; the primary endpoints were the area under the plasma concentration-time curve from 0 to infinity (AUC0-∞) and maximal plasma concentration (Cmax). Subsequently, people with overweight/obesity with or without cirrhosis (Child-Pugh class A or B) received once-weekly subcutaneous doses escalated from 0.3 mg to 6.0 mg over 24 weeks then maintained for 4 weeks; the primary endpoint was drug-related treatment-emergent adverse events, with MASH/cirrhosis-related endpoints explored. RESULTS: In the single-dose cohorts (n = 41), mean AUC0-∞ and Cmax were similar in those with cirrhosis compared with healthy individuals (90% CIs for adjusted geometric mean ratios spanned 1). Drug-related adverse events occurred in 25.0% of healthy individuals and ≤25.0% of those with cirrhosis after single doses, and 82.4% and 87.5%, respectively, of the multiple-dose cohorts (n = 41) over 28 weeks. Liver fat content, liver stiffness, liver volume, body weight, and other hepatic and metabolic disease markers were generally reduced after 28 weeks of survodutide treatment. CONCLUSIONS: Survodutide is generally tolerable in people with compensated or decompensated cirrhosis, does not require pharmacokinetic-related dose adjustment, and may improve liver-related non-invasive tests, supporting its investigation for MASH-related cirrhosis. IMPACT AND IMPLICATIONS: Survodutide is a glucagon receptor/glucagon-like peptide-1 receptor dual agonist in development for treatment of metabolic dysfunction-associated steatohepatitis (MASH), which causes cirrhosis in ∼20% of cases. This trial delineates the pharmacokinetic and safety profile of survodutide in people with compensated or decompensated cirrhosis, and revealed associated reductions in liver fat content, markers of liver fibrosis and body weight. These findings have potential relevance for people with MASH-including those with decompensated cirrhosis, who are usually excluded from clinical trials of investigational drugs. Based on this study, further investigation of survodutide for MASH-related cirrhosis is warranted. GOV IDENTIFIER: NCT05296733.
引用
- Lawitz EJ, Fraessdorf M, Neff GW, et al. Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosis. J Hepatol. 2024. PMID: 38857788. doi:10.1016/j.jhep.2024.06.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。